Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) shot up 5.3% on Monday . The company traded as high as $7.35 and last traded at $7.32. 234,742 shares were traded during trading, an increase of 15% from the average session volume of 204,805 shares. The stock had previously closed at $6.95.

AGLE has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Aeglea Bio Therapeutics in a research report on Wednesday. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. BidaskClub upgraded Aeglea Bio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Aeglea Bio Therapeutics in a report on Monday, August 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.31.

The stock has a market cap of $326.47 million, a price-to-earnings ratio of -3.39 and a beta of 1.85. The firm’s fifty day moving average price is $6.97 and its two-hundred day moving average price is $7.16.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities research analysts expect that Aeglea Bio Therapeutics Inc will post -1.75 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its holdings in Aeglea Bio Therapeutics by 150.4% during the first quarter. BNP Paribas Arbitrage SA now owns 8,073 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 4,849 shares during the period. SG Americas Securities LLC increased its position in shares of Aeglea Bio Therapeutics by 119.6% during the second quarter. SG Americas Securities LLC now owns 22,891 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 12,467 shares during the period. Assenagon Asset Management S.A. bought a new stake in Aeglea Bio Therapeutics during the second quarter valued at $3,078,000. Trexquant Investment LP purchased a new position in shares of Aeglea Bio Therapeutics during the second quarter worth about $126,000. Finally, Bank of New York Mellon Corp increased its position in shares of Aeglea Bio Therapeutics by 5.3% in the first quarter. Bank of New York Mellon Corp now owns 95,106 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 4,763 shares during the last quarter. Institutional investors own 85.10% of the company’s stock.

Aeglea Bio Therapeutics Company Profile (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: Why do earnings reports matter?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.